Share chart Quince Therapeutics, Inc.
Extended chart
Simple chart
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., биофармацевтическая компания, специализируется на разработке прецизионных терапевтических средств для изнурительных и редких заболеваний. Компания открыла обширную платформу лекарственных средств, нацеленных на кости, для точной доставки малых молекул, пептидов или больших молекул непосредственно в место перелома кости и заболевания. Его ведущим соединением является NOV004, анаболический пептид, разработанный для точного нацеливания и концентрации в месте перелома кости. Ранее компания называлась Cortexyme, Inc. more details| IPO date | 2019-05-09 |
|---|---|
| ISIN | US22053A1079 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.quincetx.com |
| Цена ао | 1.34 |
| Change price per week: | -18.03% (1.22) |
|---|---|
| Change price per month: | -29.08% (1.41) |
| Change price per 3 month: | -42.2% (1.73) |
| Change price per half year: | +29.37% (0.773) |
| Change price per year: | -0.4975% (1.005) |
| Change price per 3 year: | -79.21% (4.81) |
| Change price per 5 year: | -97.55% (40.87) |
| Change price per year to date: | -45.95% (1.85) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Tang Capital Management, LLC | 3220000 | 7.45 |
| Vanguard Group Inc | 971801 | 2.25 |
| EPIQ Capital Group, LLC | 870133 | 2.01 |
| Renaissance Technologies, LLC | 458680 | 1.06 |
| Blackrock Inc. | 335604 | 0.78 |
| Geode Capital Management, LLC | 261738 | 0.61 |
| Alphabet Inc. | 189122 | 0.44 |
| Bank of America Corporation | 170031 | 0.39 |
| Bridgeway Capital Management, Inc. | 138495 | 0.32 |
| JANE STREET GROUP, LLC | 119741 | 0.28 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Dirk Thye M.D. | CEO, Chief Medical Officer & Director | 681.36k | 1970 (55 years) |
| Mr. Brendan Hannah M.B.A. | Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer | 504.34k | 1986 (39 years) |
| Ms. Stacy Roughan | Vice President of Corporate Communications & Investor Relations | N/A | |
| Ms. Mary Ellen Sillivos | Vice President of Human Resources | N/A | |
| Dr. Stewart A. Low Ph.D. | Head of Discovery | N/A | |
| Dr. Charles S. Ryan J.D., Ph.D. | President | N/A | 1964 (61 year) |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer | N/A | |
| Mr. Giovanni Mambrini M.Sc. | Chief Technology Officer | ||
| Mr. Thomas Sabia M.B.A. | Chief Commercial Officer | ||
| Ms. Pamela M. Williamson FRAPS, M.B.A., RAC | Head of Regulatory Affairs |
Address: United States, South San Francisco. CA, 601 Gateway Blvd - open in Google maps, open in Yandex maps
Website: https://www.quincetx.com
Website: https://www.quincetx.com
